CO2020008485A2 - Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismos - Google Patents
Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismosInfo
- Publication number
- CO2020008485A2 CO2020008485A2 CONC2020/0008485A CO2020008485A CO2020008485A2 CO 2020008485 A2 CO2020008485 A2 CO 2020008485A2 CO 2020008485 A CO2020008485 A CO 2020008485A CO 2020008485 A2 CO2020008485 A2 CO 2020008485A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- constructs
- arni
- pnpla3 expression
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01051—1-Acylglycerol-3-phosphate O-acyltransferase (2.3.1.51)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Abstract
La presente invención se refiere a constructos de ARNi para reducir la expresión del gen de PNPLA3. También se describe métodos de uso de tales constructos de ARNi para tratar o prevenir enfermedad hepática, enfermedad por hígado graso no alcohólico (NAFLD) .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762597841P | 2017-12-12 | 2017-12-12 | |
PCT/US2018/065275 WO2019118638A2 (en) | 2017-12-12 | 2018-12-12 | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020008485A2 true CO2020008485A2 (es) | 2020-07-31 |
Family
ID=65139138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0008485A CO2020008485A2 (es) | 2017-12-12 | 2020-07-10 | Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismos |
Country Status (23)
Country | Link |
---|---|
US (1) | US20210139912A1 (es) |
EP (1) | EP3724337A2 (es) |
JP (2) | JP2021506238A (es) |
KR (1) | KR20200097299A (es) |
CN (1) | CN111699257A (es) |
AR (1) | AR113490A1 (es) |
AU (1) | AU2018386089A1 (es) |
BR (1) | BR112020011686A2 (es) |
CA (1) | CA3084133A1 (es) |
CL (2) | CL2020001543A1 (es) |
CO (1) | CO2020008485A2 (es) |
CR (1) | CR20200304A (es) |
EA (1) | EA202091437A1 (es) |
IL (1) | IL275029A (es) |
JO (1) | JOP20200142A1 (es) |
MX (1) | MX2020006088A (es) |
PE (1) | PE20210633A1 (es) |
PH (1) | PH12020550833A1 (es) |
SG (1) | SG11202005257UA (es) |
TW (1) | TW201938792A (es) |
UY (1) | UY38003A (es) |
WO (1) | WO2019118638A2 (es) |
ZA (1) | ZA202003982B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
TW202023573A (zh) | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
JP2022511550A (ja) * | 2018-12-10 | 2022-01-31 | アムジエン・インコーポレーテツド | PNPLA3発現を阻害するためのRNAiコンストラクト |
WO2021074772A1 (en) * | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
JP2023504744A (ja) * | 2019-12-09 | 2023-02-06 | アムジエン・インコーポレーテツド | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
TW202138559A (zh) * | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法 |
US20210301294A1 (en) * | 2020-03-26 | 2021-09-30 | Arrowhead Pharmaceuticals, Inc. | RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use |
BR112023001957A2 (pt) | 2020-08-05 | 2023-04-25 | Dicerna Pharmaceuticals Inc | Composições e métodos para inibir expressão de lpa |
EP4323519A1 (en) | 2021-04-14 | 2024-02-21 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating pnpla3 expression |
AU2022339846A1 (en) * | 2021-09-01 | 2024-03-14 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
WO1993009668A1 (en) | 1991-11-22 | 1993-05-27 | Affymax Technology N.V. | Combinatorial strategies for polymer synthesis |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
CA2335393C (en) | 1998-07-20 | 2008-09-23 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
US20100056384A1 (en) * | 2008-09-04 | 2010-03-04 | Board Of Regents, The University Of Texas System | Sequence Variations in PNPLA3 Associated with Hepatic Steatosis |
AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
JP6694382B2 (ja) | 2013-06-21 | 2020-05-13 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 標的核酸を調節するための組成物および方法 |
EP3256587A2 (en) * | 2015-02-13 | 2017-12-20 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP3350328A1 (en) * | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
-
2018
- 2018-12-11 UY UY0001038003A patent/UY38003A/es not_active Application Discontinuation
- 2018-12-11 AR ARP180103612A patent/AR113490A1/es unknown
- 2018-12-12 CA CA3084133A patent/CA3084133A1/en active Pending
- 2018-12-12 WO PCT/US2018/065275 patent/WO2019118638A2/en unknown
- 2018-12-12 CR CR20200304A patent/CR20200304A/es unknown
- 2018-12-12 PE PE2020000745A patent/PE20210633A1/es unknown
- 2018-12-12 KR KR1020207019521A patent/KR20200097299A/ko not_active Application Discontinuation
- 2018-12-12 AU AU2018386089A patent/AU2018386089A1/en active Pending
- 2018-12-12 CN CN201880088895.5A patent/CN111699257A/zh active Pending
- 2018-12-12 JO JOP/2020/0142A patent/JOP20200142A1/ar unknown
- 2018-12-12 MX MX2020006088A patent/MX2020006088A/es unknown
- 2018-12-12 JP JP2020530513A patent/JP2021506238A/ja active Pending
- 2018-12-12 EP EP18836995.3A patent/EP3724337A2/en active Pending
- 2018-12-12 BR BR112020011686-6A patent/BR112020011686A2/pt unknown
- 2018-12-12 US US16/771,907 patent/US20210139912A1/en active Pending
- 2018-12-12 EA EA202091437A patent/EA202091437A1/ru unknown
- 2018-12-12 SG SG11202005257UA patent/SG11202005257UA/en unknown
- 2018-12-12 TW TW107144746A patent/TW201938792A/zh unknown
-
2020
- 2020-06-01 IL IL275029A patent/IL275029A/en unknown
- 2020-06-05 PH PH12020550833A patent/PH12020550833A1/en unknown
- 2020-06-10 CL CL2020001543A patent/CL2020001543A1/es unknown
- 2020-06-30 ZA ZA2020/03982A patent/ZA202003982B/en unknown
- 2020-07-10 CO CONC2020/0008485A patent/CO2020008485A2/es unknown
-
2023
- 2023-08-10 CL CL2023002358A patent/CL2023002358A1/es unknown
- 2023-10-26 JP JP2023183884A patent/JP2024012386A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019118638A2 (en) | 2019-06-20 |
MX2020006088A (es) | 2020-08-24 |
AU2018386089A1 (en) | 2020-06-18 |
CL2023002358A1 (es) | 2024-02-23 |
JP2021506238A (ja) | 2021-02-22 |
SG11202005257UA (en) | 2020-07-29 |
WO2019118638A3 (en) | 2019-08-15 |
EA202091437A1 (ru) | 2020-12-29 |
JOP20200142A1 (ar) | 2022-10-30 |
JP2024012386A (ja) | 2024-01-30 |
CR20200304A (es) | 2020-09-04 |
CN111699257A (zh) | 2020-09-22 |
IL275029A (en) | 2020-07-30 |
UY38003A (es) | 2019-06-28 |
ZA202003982B (en) | 2021-07-28 |
PE20210633A1 (es) | 2021-03-23 |
CA3084133A1 (en) | 2019-06-20 |
EP3724337A2 (en) | 2020-10-21 |
PH12020550833A1 (en) | 2021-07-05 |
CL2020001543A1 (es) | 2020-08-28 |
BR112020011686A2 (pt) | 2020-11-24 |
AR113490A1 (es) | 2020-05-06 |
KR20200097299A (ko) | 2020-08-18 |
TW201938792A (zh) | 2019-10-01 |
US20210139912A1 (en) | 2021-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020008485A2 (es) | Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismos | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
CL2019000061A1 (es) | Anticuerpo para anti-claudin 18a2 y su utilización. | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
GT201400097A (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
UY36357A (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)) | |
CL2021001489A1 (es) | Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos | |
BR112019006876A2 (pt) | anticorpos e composições anti-lag-3 | |
CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
BR112016026950A2 (pt) | composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas | |
EA201791258A1 (ru) | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени | |
BR112019012342A2 (pt) | anticorpos il-11 | |
CL2022003369A1 (es) | Constructos de arni para inhibir la expresión de hsd17b13 y métodos de uso de los mismos | |
CL2021003169A1 (es) | Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas | |
PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
CL2018003515A1 (es) | Anticuerpos anti-gitr y sus usos. | |
UY37376A (es) | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso | |
BR112018003741A2 (pt) | composições biofarmacêuticas | |
ECSP18091065A (es) | Ésteres de oxaborol y sus usos | |
AR115960A1 (es) | Composiciones y métodos para inhibir la expresión del gen lect2 | |
AR103676A1 (es) | COMPOSICIONES DE ARNi QUE CONTIENEN UN DOMINIO FOSFOLIPASA TIPO PATATINA 3 (PNPLA3) Y SUS MÉTODOS DE USO | |
CL2017000872A1 (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa) |